Literature DB >> 19548388

Clinicopathologic features and outcome of the oncocytic variant of papillary thyroid carcinoma.

Menachem Gross1, Ron Eliashar, Avraham Ben-Yaakov, Jeffrey M Weinberger, Bella Maly.   

Abstract

OBJECTIVES: The purpose of this study was to define the clinicopathologic features and outcome of the oncocytic variant of papillary thyroid carcinoma (OVPTC) with a review of the literature.
METHODS: Twenty-three patients with OVPTC over a 10-year period were studied. Demographic, clinical, and histopathologic features and outcome data were analyzed retrospectively.
RESULTS: Seventeen women and 6 men, ages ranging from 20 to 76 years (95% confidence interval, 43.0 to 54.48), were studied. Cervical lymph node involvement was found in 43.4% of the patients. Most of the recurrences were associated with thyroid masses greater than 2 cm in diameter. Evaluation of the overall survival data by the Kaplan-Meier method revealed that most recurrences took place earlier than 30 months, and the majority of patients (74%) were well, with no evidence of disease, up to 78 months after the last treatment. All of the OVPTC cases presented as nonencapsulated tumors, and 78.2% demonstrated extrathyroid stromal invasion.
CONCLUSIONS: OVPTC is a unique variant of papillary thyroid carcinoma that has distinctive clinicopathologic features. Since OVPTC is often associated with local invasion and may involve cervical lymph nodes, it may require more extensive surgery than classic papillary thyroid carcinoma.

Entities:  

Mesh:

Year:  2009        PMID: 19548388     DOI: 10.1177/000348940911800510

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  5 in total

1.  Long-term outcome of rare oncocytic papillary (Hürthle cell) thyroid carcinoma following (adjuvant) initial radioiodine therapy.

Authors:  Vera Wenter; Annamirl Jellinek; Marcus Unterrainer; Freba Ahmaddy; Sebastian Lehner; Nathalie Lisa Albert; Peter Bartenstein; Thomas Knösel; Christine Spitzweg; Harun Ilhan; Andrei Todica
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-13       Impact factor: 9.236

2.  Hürthle Cell Carcinoma of the Thyroid Gland: Systematic Review and Meta-analysis.

Authors:  Andrés Coca-Pelaz; Juan P Rodrigo; Jatin P Shah; Alvaro Sanabria; Abir Al Ghuzlan; Carl E Silver; Ashok R Shaha; Peter Angelos; Dana M Hartl; Antti A Mäkitie; Kerry D Olsen; Randall P Owen; Gregory W Randolph; Ricard Simó; Ralph P Tufano; Luiz P Kowalski; Mark E Zafereo; Alessandra Rinaldo; Alfio Ferlito
Journal:  Adv Ther       Date:  2021-08-22       Impact factor: 3.845

Review 3.  Hürthle cell carcinoma: current perspectives.

Authors:  Sara Ahmadi; Michael Stang; Xiaoyin Sara Jiang; Julie Ann Sosa
Journal:  Onco Targets Ther       Date:  2016-11-07       Impact factor: 4.147

4.  Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome.

Authors:  Jelena Lukovic; Irina Petrovic; Zijin Liu; Susan M Armstrong; James D Brierley; Richard Tsang; Jesse D Pasternak; Karen Gomez-Hernandez; Amy Liu; Sylvia L Asa; Ozgur Mete
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-16       Impact factor: 5.555

5.  Variants of papillary thyroid carcinoma: association with histopathological prognostic factors.

Authors:  Fábio Muradás Girardi; Marinez Bizarro Barra; Cláudio Galleano Zettler
Journal:  Braz J Otorhinolaryngol       Date:  2013 Nov-Dec
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.